399 related articles for article (PubMed ID: 30465156)
1. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
3. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
[TBL] [Abstract][Full Text] [Related]
6. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
7. Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012.
Hannouf M; Batra A; Lupichuk S
Curr Oncol; 2021 Mar; 28(2):1137-1142. PubMed ID: 33806441
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.
Jung L; Miske A; Indorf A; Nelson K; Gadi VK; Banda K
Clin Breast Cancer; 2022 Apr; 22(3):e310-e318. PubMed ID: 34753632
[TBL] [Abstract][Full Text] [Related]
9. Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer.
Chen W; Tu Q; Shen Y; Tang K; Hong M; Shen Y
World J Surg Oncol; 2021 Feb; 19(1):52. PubMed ID: 33602236
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis.
Ding W; Li Z; Wang C; Dai J; Ruan G; Tu C
Medicine (Baltimore); 2018 Oct; 97(42):e12908. PubMed ID: 30335021
[TBL] [Abstract][Full Text] [Related]
11. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
[TBL] [Abstract][Full Text] [Related]
12. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.
Bines J; Small IA; Sarmento R; Kestelman F; Silva S; Rodrigues FR; Faroni L; Gonçalves A; Ebecken E; Maroun P; Millen E; Bonamino M
Oncologist; 2020 Sep; 25(9):758-764. PubMed ID: 32476183
[TBL] [Abstract][Full Text] [Related]
13. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
15. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
;
Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
[TBL] [Abstract][Full Text] [Related]
17. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
de Gregorio A; Janni W; Friedl TWP; Nitz U; Rack B; Schneeweiss A; Kates R; Fehm T; Kreipe H; Christgen M; Kümmel S; Trapp E; Wuerstlein R; Hartkopf A; Clemens M; Reimer T; Häberle L; Fasching PA; Gluz O; Harbeck N
Br J Cancer; 2022 Jun; 126(12):1715-1724. PubMed ID: 35194193
[TBL] [Abstract][Full Text] [Related]
18. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
19. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Nitz U; Gluz O; Clemens M; Malter W; Reimer T; Nuding B; Aktas B; Stefek A; Pollmanns A; Lorenz-Salehi F; Uleer C; Krabisch P; Kuemmel S; Liedtke C; Shak S; Wuerstlein R; Christgen M; Kates RE; Kreipe HH; Harbeck N;
J Clin Oncol; 2019 Apr; 37(10):799-808. PubMed ID: 30785826
[TBL] [Abstract][Full Text] [Related]
20. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
